Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
Volume 1.06M
Average 0.99M
CGEM Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Cullinan Therapeutics, Inc.NASDAQ: CGEM
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$53.7M, compared with -$55M a year earlier. Trailing-twelve-month operating income was -$240.35M.
Context
- Operating income increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 7 analysts of -$204.35M (+15.4%) for the fiscal year ending Dec 2026, a step up from the -22.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$53.7M+2.8% QoQ
- Last fiscal yearDec 2025
- -$241.65M-22.7% YoY
- LTMMar 2026
- -$240.35M-15.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.4% | +31.9% | +29.5 pp |
| 1 year | -22.7% | +15.4% | +38.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (241.65M) USD
- Year-over-year change
- -22.7%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (241.65M) | -22.7% |
| FY2024 | 2024-12-31 | (196.92M) | -3.1% |
| FY2023 | 2023-12-31 | (191.09M) | -232.1% |
| FY2022 | 2022-12-31 | 144.65M | +312.9% |
| FY2021 | 2021-12-31 | (67.95M) | — |
Operating Income vs competitors
How CGEM compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -15.0% is the 8th highest of 11, against a peer median of +19.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $289.66M USD | +208.4% | — | 41.3% | |
| LTM Sep 2026 | $34.1M USD | +117.9% | — | 2.5% | |
| LTM Mar 2026 | $30.7M USD | +307.5% | — | 42.3% | |
| LTM Mar 2026 | -$63.66M USD | +36.0% | — | 40.5% | |
| LTM Mar 2026 | -$91.17M USD | +33.2% | — | — | |
| LTM Mar 2026 | -$118.48M USD | +5.6% | — | 149.6% | |
| LTM Mar 2026 | -$156.87M USD | -11.7% | — | — | |
| LTM Mar 2026 | -$156.98M USD | -38.2% | — | 726.3% | |
| LTM Mar 2026 | -€212.71M EUR | -251.5% | — | 570.3% | |
| LTM Jun 2026 | -$216.08M USD | -69.5% | — | 205.8% | |
| LTM Mar 2026 | -$240.35M USD | -15.0% | — | — | |
| Peer median (excluding CGEM) | — | +19.4% | — | 96.0% | |
Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.94M | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 306K | 0 |
| Gross Profit | 18.94M | 0 | 0 | (306K) | 0 |
| Gross Margin | 100.0% | — | — | — | — |
| Research & Development | 57.75M | 91.95M | 148.16M | 142.9M | 187.4M |
| Selling, General & Admin | 29.15M | 40.19M | 42.49M | 53.71M | 54.25M |
| Operating Expenses | 86.9M | (144.65M) | 191.09M | 196.61M | 241.65M |
| Depreciation & Amortization | 53K | 93K | 310K | 306K | 311K |
| EBITDA | (67.43M) | (132.04M) | (190.34M) | (167.15M) | (219.57M) |
| EBITDA Margin | -356.0% | — | — | — | — |
| Operating Income | (67.95M) | 144.65M | (191.09M) | (196.92M) | (241.65M) |
| Operating Margin | -358.7% | — | — | — | — |
| Interest Income | 477K | 6.61M | 21.63M | 29.66M | 22.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 469K | 6.67M | 21.87M | 29.46M | 21.77M |
| Income Before Tax | (67.49M) | 151.32M | (169.22M) | (167.46M) | (219.88M) |
| Pre-Tax Margin | -356.3% | — | — | — | — |
| Income Tax Expense | 0 | 42.12M | (14.12M) | 117K | 0 |
| Net Income | (65.57M) | 111.21M | (153.16M) | (167.38M) | (219.88M) |
| Net Margin | -346.1% | — | — | — | — |
| EPS (Basic) | (1.48) | 2.46 | (3.69) | (3.11) | (3.72) |
| EPS (Diluted) | (1.48) | 2.38 | (3.69) | (3.11) | (3.72) |
| Weighted Avg Shares | 44.29M | 45.16M | 41.51M | 53.77M | 59.05M |
| Weighted Avg Shares (Diluted) | 44.29M | 46.64M | 41.55M | 53.77M | 59.05M |
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
Intrinsic Alpha fair value
Locked
Current Price
$9.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.